Centogene Launches Two Year Global Parkinson’s Disease Study

Centogene Launches Two Year Global Parkinson’s Disease Study

Publication date: May 14, 2019

Patients displaying mutations in PD genes will have the option to undergo further clinical assessment in a supplementary study, ‘LRRK2 International Parkinson’s Disease Project (LIPAD)’, conducted at the University of LcFCbeck with the lead of Professor Christine Klein, where a detailed phenotyping of participants will be performed in order to describe the frequency of all important clinical PD signs and symptoms.

Patients enrolled in ROPAD with a LRRK2 mutation may also be offered participation in future clinical studies with study partner Denali Therapeutics, which is developing investigational therapies for the treatment of neurodegenerative and other human diseases.

-CENTOGENE is committed to bringing hope to patients and their families by shortening the diagnostic odyssey, and we are proud to be working on this important study that may have vast implications for the future diagnosis and treatment of Parkinson’s disease,” said Dr. Arndt Rolfs, Chief Executive Officer and Founder of CENTOGENE.

Concepts Keywords
Biochemical LRRK2
Biomarkers Parkinson’s disease
Blood Medicine
CEO Health
Chief Executive Officer Medical specialties
Cohort Rare disease
Denali Investigational therapies
Epidemiological Hope rare diseases
Frequency Common neurodegenerative disorders
Genetic
Genetic Mutations
Genetics
Germany
Heterogeneity
Mutation
Neurodegenerative
Neurodegenerative Diseases
Neurodegenerative Disorders
Orphan Drugs
Parkinson
Rationality
Rostock

Semantics

Type Source Name
disease MESH neurodegenerative disorders
drug DRUGBANK Nonoxynol-9
disease MESH development
gene UNIPROT THEMIS
gene UNIPROT KIT
gene UNIPROT LRRK2
gene UNIPROT GBA
disease MESH diagnosis
gene UNIPROT WDFY2
disease MESH rare disease

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *